Lundbeck A/S third quarter revenue increases 7% to DKK 3,619 million

Danish-based H. Lundbeck A/S, a pharmaceutical company specialized in central nervous system (CNS) disorders, reports third quarter revenue of DKK 3,619 million, an increase of 7% compared to the third quarter results of 2009.

Profit from operations (EBIT) was DKK 846 million, an increase of 8% compared to the same period last year. The EBIT margin for the quarter was 23.4%. Continued strong growth in key products Cipralex®, Ebixa® and Azilect®, growing 11%, 9% and 28% respectively. Available video includes Lundbeck headquarters shot and general views of laboratories.

SOURCE thenewsmarket.com